tradingkey.logo
tradingkey.logo

Upexi Inc

UPXI
1.000USD
-0.070-6.54%
Close 03/27, 16:00ETQuotes delayed by 15 min
710.42KMarket Cap
LossP/E TTM

Upexi Inc

1.000
-0.070-6.54%

More Details of Upexi Inc Company

Upexi, Inc. is a solana-focused treasury company. The Company is a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space. The Company’s brands include Lucky Tail, PRAX, and Cure Mushrooms. Lucky Tail is a pet care product brand that provides products from grooming tools to nutritional products. Cure Mushrooms is a full line of medicinal mushroom products, designed by effect for consumers, which offers mushroom extracts in tinctures and gummies. PRAX is a full line of medicinal mushroom products, designed by effect for consumers, which are cultivated, extracted, and produced in the United States. Its products are distributed in the United States of America and internationally through multiple entities and managed through locations in Florida.

Upexi Inc Info

Ticker SymbolUPXI
Company nameUpexi Inc
IPO dateJun 24, 2021
CEOMarshall (Allan)
Number of employees59
Security typeOrdinary Share
Fiscal year-endJun 24
Address3030 Rocky Point Drive
CityTAMPA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33607
Phone17013535425
Websitehttps://upexi.com/
Ticker SymbolUPXI
IPO dateJun 24, 2021
CEOMarshall (Allan)

Company Executives of Upexi Inc

Name
Name/Position
Position
Shareholding
Change
Allan Marshall ,
Allan Marshall ,
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.31M
+6.04%
Dr. Gene Salkind, M.D.
Dr. Gene Salkind, M.D.
Independent Director
Independent Director
685.37K
+14.59%
Mr. Andrew J. Norstrud
Mr. Andrew J. Norstrud
Chief Financial Officer, Director
Chief Financial Officer, Director
589.14K
+40.74%
Mr. Thomas Charles Williams
Mr. Thomas Charles Williams
Independent Director
Independent Director
100.00K
--
Mr. Lawrence H. Dugan
Mr. Lawrence H. Dugan
Independent Director
Independent Director
--
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Allan Marshall ,
Allan Marshall ,
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.31M
+6.04%
Dr. Gene Salkind, M.D.
Dr. Gene Salkind, M.D.
Independent Director
Independent Director
685.37K
+14.59%
Mr. Andrew J. Norstrud
Mr. Andrew J. Norstrud
Chief Financial Officer, Director
Chief Financial Officer, Director
589.14K
+40.74%
Mr. Thomas Charles Williams
Mr. Thomas Charles Williams
Independent Director
Independent Director
100.00K
--
Mr. Lawrence H. Dugan
Mr. Lawrence H. Dugan
Independent Director
Independent Director
--
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q1
By BusinessUSD
Name
Revenue
Proportion
Internally manufactured
2.21M
69.93%
Contract manufactured
925.07K
29.31%
Purchased as finished goods
23.95K
0.76%
By RegionUSD
Name
Revenue
Proportion
United States of America
3.09M
97.97%
Other
64.15K
2.03%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Internally manufactured
2.21M
69.93%
Contract manufactured
925.07K
29.31%
Purchased as finished goods
23.95K
0.76%

Shareholding Stats

Updated: Thu, Feb 19
Updated: Thu, Feb 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Samara Special Opportunities
6.49%
Marshall (Allan)
4.75%
Marex Group plc
4.73%
Arrington Capital Investment Management, LLC
3.96%
GSR Growth Investments LP
3.85%
Other
76.22%
Shareholders
Shareholders
Proportion
Samara Special Opportunities
6.49%
Marshall (Allan)
4.75%
Marex Group plc
4.73%
Arrington Capital Investment Management, LLC
3.96%
GSR Growth Investments LP
3.85%
Other
76.22%
Shareholder Types
Shareholders
Proportion
Corporation
10.34%
Investment Advisor
10.10%
Individual Investor
8.09%
Hedge Fund
8.01%
Investment Advisor/Hedge Fund
5.39%
Research Firm
2.95%
Bank and Trust
0.40%
Venture Capital
0.22%
Pension Fund
0.15%
Other
54.36%

Institutional Shareholding

Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
98
14.39M
22.84%
-8.99M
2025Q3
60
18.50M
31.42%
+11.94M
2025Q2
46
10.18M
21.50%
+7.63M
2025Q1
42
311.78K
28.56%
-35.31K
2024Q4
42
307.62K
23.29%
-32.82K
2024Q3
40
303.51K
29.16%
-55.91K
2024Q2
40
319.39K
30.68%
-45.58K
2024Q1
42
328.34K
32.32%
-46.59K
2023Q4
42
319.26K
31.43%
-34.26K
2023Q3
40
369.15K
37.28%
-46.01K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Samara Special Opportunities
4.53M
7.16%
+4.53M
--
Aug 29, 2025
Marshall (Allan)
3.31M
5.24%
+200.00K
+6.42%
Dec 23, 2025
Marex Group plc
644.18K
1.02%
+644.18K
--
Sep 30, 2025
GSR Growth Investments LP
2.69M
4.25%
+380.35K
+16.49%
Sep 30, 2025
MMCAP Asset Management
766.93K
1.21%
-12.17M
-94.07%
Sep 30, 2025
Jane Street Capital, L.L.C.
614.87K
0.97%
+614.87K
--
Sep 30, 2025
Millennium Management LLC
365.96K
0.58%
-19.30K
-5.01%
Sep 30, 2025
Rudick (Brian Benjamin)
838.60K
1.33%
+400.00K
+91.20%
Jul 16, 2025
Susquehanna International Group, LLP
751.48K
1.19%
+637.36K
+558.48%
Sep 30, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
Sep 27, 2024
Merger
20→1
Sep 27, 2024
Merger
20→1
Sep 27, 2024
Merger
20→1
Sep 27, 2024
Merger
20→1
Date
Ex-dividend Date
Type
Ratio
Sep 27, 2024
Merger
20→1
Sep 27, 2024
Merger
20→1
Sep 27, 2024
Merger
20→1
Sep 27, 2024
Merger
20→1
KeyAI